Comparative Pharmacology
Head-to-head clinical analysis: HEPTALAC versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPTALAC versus SUFLAVE.
HEPTALAC vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia scavenger; lactulose is metabolized by colonic bacteria to organic acids, acidifying the colon, which converts NH3 to NH4+ and promotes ammonia excretion. Lactulose also reduces colonic transit time and bacterial production of ammonia.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Oral: 3.33 g (30 mL) 3 times daily. Rectal: 200 mL of 30% solution as retention enema, 3 times daily. Intravenous: 30 g as a single dose via intra-abdominal instillation.
250 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal hepatic function; prolonged in hepatic encephalopathy due to altered clearance (up to 24 hours).
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily renal (approximately 70-80%) as unchanged drug; minor biliary/fecal elimination (20-30%).
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative